European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …
inhibitors, mandate regular updating of concepts and management. A European …
[HTML][HTML] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintas-Cardama, J Mercer… - Leukemia, 2013 - nature.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …
myelogenous leukemia (CML) is generally associated with decreased response to tyrosine …
Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP
M Baccarani, E Abruzzese, V Accurso… - Blood …, 2019 - ashpublications.org
Several papers authored by international experts have proposed recommendations on the
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …
management of BCR-ABL1+ chronic myeloid leukemia (CML). Following these …
[PDF][PDF] Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation
LW Teperman, F Poordad, N Bzowej… - Liver …, 2013 - Wiley Online Library
Long‐term prophylaxis with hepatitis B immunoglobulin (HBIG) for the prevention of hepatitis
B virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients with chronic …
B virus (HBV) recurrence after orthotopic liver transplantation (OLT) in patients with chronic …
The argument for using imatinib in CML
S Claudiani, JF Apperley - Hematology 2014, the American …, 2018 - ashpublications.org
June 2018 was the 20th anniversary of the clinical use of the first tyrosine kinase inhibitor
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
(TKI), imatinib, for chronic myeloid leukemia. Since then, the change in prognosis for …
First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
VG Oehler - Hematology 2014, the American Society of …, 2020 - ashpublications.org
In 2020, for the great majority of patients with chronic phase chronic myeloid leukemia
(CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled …
(CML), life expectancy is unaffected by a diagnosis of CML because of the unparalleled …
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression
RE Clark, JF Apperley, M Copland… - Blood Advances, 2021 - ashpublications.org
At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as
to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia …
to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia …
Clinical and prognostic significance of 3q26. 2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
W Wang, JE Cortes, P Lin, MW Beaty… - Blood, The Journal …, 2015 - ashpublications.org
Abstract Chromosome 3q26. 2 abnormalities in acute myeloid leukemia, including inv (3)/t
(3; 3) and t (3; 21), have been studied and are associated with a poor prognosis. Their …
(3; 3) and t (3; 21), have been studied and are associated with a poor prognosis. Their …
Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
The high fatality of patients with blast phase (BP) chronic myeloid leukemia (CML)
necessitates identification of high-risk (HR) patients to prevent onset of BP. Here, we …
necessitates identification of high-risk (HR) patients to prevent onset of BP. Here, we …